ALR Technologies Announces Development Partnership Agreement With Insulin Algorithms; Successful Integration of the Two Techn...
05 Novembro 2013 - 11:18AM
Marketwired
ALR Technologies Announces Development Partnership Agreement With
Insulin Algorithms; Successful Integration of the Two Technology
Platforms Could Lead to Near-Instantaneous Insulin Dosage
Consultation and Adjustment
RICHMOND, VA--(Marketwired - Nov 5, 2013) - ALR Technologies
(OTCBB: ALRT) and Insulin Algorithms (InsulinAlgo) announced a
technology partnership that would integrate Insulin Algorithm's
insulin dosage adjustment software with ALRT's Health-e-Connect
remote monitoring platform. An integration of the two technology
platforms would create a revolutionary system that would allow
patients to remotely upload their blood glucose data to the ALRT
platform and then, within seconds, the patient's physician could be
provided with an insulin dosage recommendation electronically when
the patient's blood glucose data and patient profile were run
through the Insulin Algorithm software. Proper dosing of insulin is
one of the most important and challenging tasks in diabetes care
and an effective system to dose insulin would reduce adverse
events, improve outcomes and reduce the costs of care for patients
living with diabetes.
ALRT's platform has received FDA 510(k) clearance but any
commercial use of Insulin Algorithms' software will require
additional U.S. Food and Drug Administration regulatory clearance.
Under the agreement, ALRT will have access to the InsulinAlgo
software to begin the integration process while InsulinAlgo's FDA
clearance is pending. Once integrated and tested, and after final
FDA clearance, the ALRT-InsulinAlgo system will be made available
to the commercial marketplace both in the U.S. and
internationally.
Insulin Algorithm's Founder and Chief Medical Officer, Dr. Mayer
B. Davidson, said: "We are very excited about our partnership with
ALRT. I have spent a career studying how to properly dose insulin
and our algorithms embody that experience. This partnership with
ALRT represents the potential to offer our expertise to many
providers quickly and electronically, without the inconvenience of
paper logbooks and unnecessary additional physician visits. We hope
to serve as an experienced resource for those physicians who are on
the front line of diabetes care."
ALRT's CEO Sidney Chan said: "We are honored to partner with
Insulin Algorithms as its founder is one of the world's most
renowned experts on the proper use of insulin. As the global
pandemic has spread from the developed world to the emerging
economies, we believe there is an urgent need to provide physicians
and patients with the benefit of the very best thinking about
proper insulin dosing. Our partnership has the potential to bring
this knowledge as quickly and efficiently as a text message. We
believe there is a worldwide market for this tool."
About Insulin Algorithms
Based on Dr. Mayer B. Davidson's 35 years of diabetes research,
Insulin Algorithms has created software that will make specific
insulin dosage adjustment recommendations based on the patient's
current physical characteristics, insulin regimen, and the hundreds
of individual readings they have every month. Dr. Davidson is
Professor of Medicine at both the David Geffen School of Medicine
at UCLA and Charles R. Drew University. Dr. Davidson was President
of the American Diabetes Association in 1997-1998. A renowned
researcher and speaker on type 2 diabetes and insulin resistance,
Dr. Davidson has presented hundreds of lectures nationally and
internationally. He has served on the Editorial Boards of
Diabetes Care, Diabetes Spectrum, Clinical Diabetes, Diabetes
Reports, Today in Medicine, Geriatrics and the Journal of
Clinical Endocrinology and Metabolism and was a Consulting
Editor of Hippocrates and an Associate Editor of Endo
Trends. He currently serves on the Editorial Board of
Diabetes Research & Clinical Practice. Further, Dr.
Davidson was the Founding Editor of Current Diabetes
Reports and was the Editor-in-Chief of Diabetes Care
from 2002 through 2006, the leading clinical journal for the
diabetes community. Dr. Davidson's contributions to the medical
literature include 3 books on diabetes care, 168 scientific
papers, 31 book chapters, 59 reviews and 54 editorials and invited
articles. More information about Insulin Algorithms, Inc. can be
found at www.insulinalgorithms.com.
About ALR Technologies Inc.
ALR Technologies is a medical device company providing remote
monitoring and care facilitation for patients with chronic
diseases. ALRT has developed the FDA-cleared and HIPAA compliant
Health-e-Connect System that collects data from blood glucose
meters and uploads to a secure website. Trained Facilitators use
the System to effect efficiency of care among patients, clinicians
and caregivers to improve outcomes and assist health plans to
optimize their HEDIS goals. Currently, the Company is focused on
diabetes and will expand its services to cover other chronic
diseases anchored on verifiable data. More information about ALR
Technologies, Inc. can be found at www.alrt.com.
This release contains certain "forward-looking statements"
relating to ALR Technologies' business, and these statements
reflect the current views of ALR Technologies with respect to
future events and are subject to certain risks, uncertainties and
assumptions. When used, the words "estimate", "expect",
"anticipate", "believe" and similar expressions are intended to
identify such forward-looking statements. There are many factors
that could cause the actual results, performance or achievements of
ALR Technologies and its products to be materially different from
any future results, performances or achievements that may be
expressed or implied by such forward-looking statements. Further
management discussions of risks and uncertainties can be found in
the company's quarterly filings with the Securities Exchange
Contact: Bill Smith bill.smith@alrt.com 203.762.1073
ALR Technologies (QB) (USOTC:ALRT)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
ALR Technologies (QB) (USOTC:ALRT)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024